Literature DB >> 19109831

The validity of EQ-5D US preference weights in liver transplant candidates and recipients.

Robert T Russell1, Irene D Feurer, Panarut Wisawatapnimit, C Wright Pinson.   

Abstract

Health utility instruments assess patients' valuation of specific health states, which can be converted to quality-adjusted life years for cost-utility analysis. Data from the EQ-5D, a generic health-related quality of life questionnaire from EuroQoL, can be reported as 5 health status scores or as a single health preference weight (HPW). US population-based HPWs were published by Shaw and colleagues in 2005 (Med Care 2005;43:203-220). Our aim was to test the validity of US EQ-5D HPWs and health status scores in liver transplant patients. EQ-5D scores were converted to HPWs with Shaw et al.'s model. Data were stratified by measurement period: pretransplant period, early posttransplant period (< or =12 months), intermediate posttransplant period (13-36 months), and late posttransplant period (>36 months). EQ-5D scores were compared to specific, hypothesized Short Form 36 Health Survey, Center for Epidemiologic Studies Depression Scale, and Beck Anxiety Inventory scores that were identified a priori on the basis of construct similarity. Criterion-related and construct validity were tested with nonparametric methods. Two hundred eighty-five adults participated (113 in the pretransplant period, 60 in the early posttransplant period, 47 in the intermediate posttransplant period, and 65 in the late posttransplant period), and follow-up averaged 36 +/- 36 months. Eighty-one percent of the hypothesized relationships between EQ-5D and gold-standard scales were strong (r > or = |0.5|, P < 0.001), and the remainder were moderate (r > |0.3|, P < 0.001). Differences between pretransplant and posttransplant EQ-5D HPWs were statistically significant. In conclusion, EQ-5D dimensions and the health utility index generated from Shaw's US population preference weights demonstrated criterion-related and construct validity in liver transplant patients. It is a valid instrument for cost-utility analysis in this setting. Copyright 2008 AASLD.

Entities:  

Mesh:

Year:  2009        PMID: 19109831     DOI: 10.1002/lt.21648

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  7 in total

1.  Mapping chronic liver disease questionnaire scores onto SF-6D utility values in patients with primary sclerosing cholangitis.

Authors:  Evangelos Kalaitzakis; Maria Benito de Valle; Monira Rahman; Björn Lindkvist; Einar Björnsson; Roger Chapman; Nick Kontodimopoulos
Journal:  Qual Life Res       Date:  2015-10-15       Impact factor: 4.147

2.  Health-related quality of life, uncertainty and coping strategies in solid organ transplant recipients during shielding for the COVID-19 pandemic.

Authors:  Siobhan C McKay; Hanns Lembach; Angus Hann; Kelvin Okoth; Joy Anderton; Krishnarajah Nirantharakumar; Laura Magill; Barbara Torlinska; Matthew Armstrong; Jorge Mascaro; Nicholas Inston; Thomas Pinkney; Aaron Ranasinghe; Richard Borrows; James Ferguson; John Isaac; Melanie Calvert; M Thamara P R Perera; Hermien Hartog
Journal:  Transpl Int       Date:  2021-09-16       Impact factor: 3.842

3.  Comparison of direct-measured and derived short form six dimensions (SF-6D) health preference values among chronic hepatitis B patients.

Authors:  Carlos K H Wong; Elegance T P Lam; Cindy L K Lam
Journal:  Qual Life Res       Date:  2013-04-06       Impact factor: 4.147

4.  Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases.

Authors:  Luciana Scalone; Roberta Ciampichini; Stefano Fagiuoli; Ivan Gardini; Francesco Fusco; Laura Gaeta; Anna Del Prete; Giancarlo Cesana; Lorenzo G Mantovani
Journal:  Qual Life Res       Date:  2012-11-29       Impact factor: 4.147

5.  Head-to-Head Comparison of EQ-5D-3L and EQ-5D-5L Health Values.

Authors:  Anna Selivanova; Erik Buskens; Paul F M Krabbe
Journal:  Pharmacoeconomics       Date:  2018-06       Impact factor: 4.981

6.  Patients undergoing subacute rehabilitation have accurate expectations of their health-related quality of life at discharge.

Authors:  Steven McPhail; Terry Haines
Journal:  Health Qual Life Outcomes       Date:  2012-08-17       Impact factor: 3.186

7.  Cost-Utility Analysis of Vasoconstrictors Plus Albumin in the Treatment of Thai Patients with Type 1 Hepatorenal Syndrome.

Authors:  Sermsiri Sangroongruangsri; Kankamon Kittrongsiri; Phunchai Charatcharoenwitthaya; Abhasnee Sobhonslidsuk; Usa Chaikledkaew
Journal:  Clinicoecon Outcomes Res       Date:  2021-07-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.